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TAXUS III Trial
In-Stent Restenosis Treated With Stent-Based Delivery of Paclitaxel
Incorporated in a Slow-Release Polymer Formulation
Kengo Tanabe, MD; Patrick W. Serruys, MD, PhD; Eberhard Grube, MD; Pieter C. Smits, MD, PhD;
Guido Selbach, MD; Willem J. van der Giessen, MD, PhD; Manfred Staberock, MD;
Pim de Feyter, MD, PhD; Ralf Müller, MD; Evelyn Regar, MD; Muzaffer Degertekin, MD;
Jurgen M.R. Ligthart, MSc; Clemens Disco, MSc; Bianca Backx, PhD; Mary E. Russell, MD
Background—The first clinical study of paclitaxel-eluting stent for de novo lesions showed promising results. We
performed the TAXUS III trial to evaluate the feasibility and safety of paclitaxel-eluting stent for the treatment of
in-stent restenosis (ISR).
Methods and Results—The TAXUS III trial was a single-arm, 2-center study that enrolled 28 patients with ISR meeting
the criteria of lesion length 30 mm, 50% to 99% diameter stenosis, and vessel diameter 3.0 to 3.5 mm. They were
treated with one or more TAXUS NIRx paclitaxel-eluting stents. Twenty-five patients completed the angiographic
follow-up at 6 months, and 17 of these underwent intravascular ultrasound (IVUS) examination. No subacute stent
thrombosis occurred up to 12 months, but there was one late chronic total occlusion, and additional 3 patients showed
angiographic restenosis. The mean late loss was 0.54 mm, with neointimal hyperplasia volume of 20.3 mm3. The major
adverse cardiac event rate was 29% (8 patients; 1 non–Q-wave myocardial infarction, 1 coronary artery bypass grafting,
and 6 target lesion revascularization [TLR]). Of the patients with TLR, 1 had restenosis in a bare stent implanted for
edge dissection and 2 had restenosis in a gap between 2 paclitaxel-eluting stents. Two patients without angiographic
restenosis underwent TLR as a result of the IVUS assessment at follow-up (1 incomplete apposition and 1 insufficient
expansion of the stent).
Conclusions—Paclitaxel-eluting stent implantation is considered safe and potentially efficacious in the treatment of ISR.
IVUS guidance to ensure good stent deployment with complete coverage of target lesion may reduce reintervention.
(Circulation. 2003;107:559-564.)
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The development of coronary stents has revolutionized thefield of interventional cardiology by reducing the inci-
dence of restenosis after balloon angioplasty.1,2 With the
widespread clinical use of coronary stents, in-stent restenosis
(ISR) has become the most challenging problem.3 Previous
pharmacological and mechanical approaches have shown
disappointing results in eliminating this iatrogenic disease.
Presently, intravascular brachytherapy is the only treatment
for ISR proven to be effective in clinical randomized trials.4–6
Brachytherapy requires special handling and is hampered by
potential issues such as edge restenosis,7,8 late thrombosis,9
geographical miss,10 late stent malapposition,11 persisting
dissection,12,13 and positive vascular remodeling after
treatment.14,15
Stent-based local drug delivery is expected to cause a
revolutionary change in the field of percutaneous interven-
tion, with recent clinical trials of paclitaxel or sirolimus-
eluting stents demonstrating promising results in the treat-
ment of de novo lesions.16–19 Paclitaxel is a microtubule
inhibitor presently used to treat several kinds of cancer, most
commonly breast and ovarian. Microtubular dynamics regu-
late many of the inflammatory and profibrotic steps impli-
cated in the restenotic cascade. This agent has been reported
to reduce vascular cell proliferation and migration in vitro
and in vivo.20–23 In accordance with these experimental
results, paclitaxel-eluting stents for de novo lesions showed
no restenosis in the TAXUS I feasibility trial.16 However, it
has not been established whether this is applicable to a more
complex patient group, such as patients with ISR. The
TAXUS III trial is a single-arm, 2-center study aiming to
evaluate the feasibility and safety of this eluting stent for the
treatment of ISR.
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Patients were eligible if they had ISR of a native coronary artery with
objective evidence of ischemia. Angiographic inclusion criteria were
lesion length 30 mm, 50% to 99% diameter stenosis, and vessel
diameter between 3.0 and 3.5 mm. Patients were excluded if they had
an acute myocardial infarction, left ventricular ejection fraction
30%, stroke within the last 6 months, a renal dysfunction (serum
creatinine 1.7 g/100 mL), or a contraindication to aspirin,
clopidogrel, or ticlopidine. Between May 2001 and August 2001,
patients were enrolled in two centers (Thoraxcenter, Rotterdam, the
Netherlands, and Heart Center Siegburg, Siegburg, Germany). All
patients gave written informed consent. The study was reviewed and
approved by both institutions’ ethics review committees.
Procedure
The stent used in the study was the TAXUS NIRx paclitaxel-eluting
stent (Boston Scientific Corporation), with a total load of 1.0
g/mm2 of paclitaxel incorporated into a slow-release copolymer
carrier system that gives biphasic release. The initial release is over
the first 48 hours followed by slow release over the next 10 days. All
stents were 15 mm long and 3.0 or 3.5 mm in diameter. Balloon
predilatation was performed followed by NIRx paclitaxel-eluting
stent implantation using conventional techniques. Postdilatation was
performed if necessary. Periprocedural intravenous heparin was
given to maintain an activated clotting time 250 seconds, and all
patients received aspirin (at least 75 mg) and clopidogrel (300 mg
loading dose followed by 75 mg once daily for 6 months).
Follow-Up
Clinical information was collected 6 and 12 months after procedure.
Angiographic and intravascular ultrasound (IVUS) follow-ups were
performed at the 6-month visit. Major adverse cardiac events
(MACEs) were defined as death, myocardial infarction (MI), target-
vessel repeat percutaneous coronary intervention, or coronary artery
bypass grafting (CABG). MI was defined as Q-wave MI (develop-
ment of new pathological Q waves in 2 or more leads with CK-MB
levels elevated above normal) or non–Q-wave MI (elevation of CK
levels to 2 times upper normal limit with CK-MB levels elevated
above normal).
Angiographic Analysis
Coronary angiograms were obtained in multiple views after intracor-
onary nitrate. ISR was classified according to a modified Mehran
classification.3 Three coronary segments underwent quantitative
angiography: in-stent, proximal edge, and distal edge segment. The
in-stent analysis encompassed the entire length of all stents used
during the procedure. The proximal and distal edge segments
included up to 5 mm on either side of the in-stent segment.
Quantitative coronary angiographic analysis was performed by an
independent core laboratory (Cardialysis, Rotterdam, the Nether-
lands).24 The reference vessel diameter, minimal lumen diameter
(MLD), and percent diameter stenosis were measured before proce-
dure, after procedure, and at follow-up. Late loss was calculated as
the difference between the MLD after procedure and that at follow-
up. The target lesion was defined as the in-stent segment plus the
proximal and distal edge segments. Angiographic restenosis was
defined as 50% diameter stenosis within the target lesion.
IVUS Analysis
IVUS images were acquired after procedure and at 6-month
follow-up using automated pull-back at 0.5 mm/s following intracor-
onary nitrate.25 The total coronary analysis segment beginning 5 mm
distal to and extending 5 mm proximal to the study stent was
examined. A computer-based contour detection program was used
for automated 3D reconstruction of the segments from up to 200
cross-sectional images. Lumen, stent boundaries, and external elastic
membrane were detected using a minimum cost algorithm, and
volumetric quantification was performed.26,27 Percent volume ob-
struction was calculated as neointimal volume/stent volume100.
The quantitative ultrasound analysis was performed by the same
independent core laboratory.
Statistical Analysis
Continuous variables are expressed as meanSD. Comparisons
between postprocedure and 6-month follow-up measurements were
performed with a 2-tailed paired t test. P0.05 was considered
statistically significant.
Results
Baseline Clinical and Lesion Characteristics
Twenty-eight patients with 28 target lesions were included.
The patients’ baseline clinical and lesion characteristics are
summarized in Tables 1 and 2, respectively. The incidence of
diabetes, previous MI, and previous CABG are in keeping
with the higher risk population of ISR.3 Diffuse ISR pattern
TABLE 1. Baseline Clinical Characteristics
Patients 28
Age, y 63.210.5
Male sex 19 (67.9)
Diabetes mellitus 4* (14.3)
Hypertension 18 (64.3)
Hypercholesterolemia 20 (71.4)
Family history 5 (17.9)
Current smoker 2 (7.1)
Unstable angina pectoris 2 (7.1)
Multivessel disease 7 (25)
Previous MI 16 (57.1)
Previous CABG 5 (17.9)
Values are presented as numbers (relative percentages) or meanSD.
*In 1 patient, the information on diabetes mellitus was unknown.
TABLE 2. Lesion Characteristics
No. of target lesions 28
Treated vessel
Left anterior descending 10 (35.7)
Left circumflex 6 (21.4)
Right coronary artery 11 (39.3)
Left main 1 (3.6)
Type of ISR, Mehran classification
IA, gap 0 (0)
IB, margin 3 (10.7)
IC, focal body 6 (21.4)
ID, multifocal 1 (3.6)
II, diffuse intrastent 13 (46.4)
III, proliferative 4 (14.3)
IV, total occlusion 1 (3.6)
Lesion length, mm 13.616.36
No. of implanted paclitaxel-eluting stents
1 Stent per lesion 15 (53.6)
2 Stents per lesion 13 (46.4)
Values are presented as numbers (relative percentages) or meanSD.
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was present in 64% of target lesions. Thirteen lesions (46%)
were treated with 2 paclitaxel-eluting stents.
Clinical Outcome
Table 3 summarizes MACE up to 12 months after procedure.
No subacute stent thrombosis occurred, and no deaths were
reported. There was 100% technical success in deploying the
study stents; however, 1 patient had postprocedural non–Q-
wave MI, yielding a 30-day MACE rate of 4%.
During the 6-month follow-up, an additional 7 patients had
a MACE, for a 6-month rate of 29%. One patient underwent
CABG attributable to progression of left main and ostial left
circumflex lesions, which were at a distance from the target
lesion. The remaining 6 patients underwent percutaneous
target lesion revascularization (TLR). For 3 of these patients,
the indication for TLR was angiographic restenosis. In the
remaining 3 patients, 1 without angiographic restenosis had
TLR because of anginal symptoms in the presence of a small
MLD (1.33 mm). IVUS findings at follow-up triggered 2
additional interventions in the absence of angiographic reste-
nosis. One showed incomplete stent apposition, the other
showed insufficient stent expansion, and neither showed
neointimal hyperplasia (percent volume obstruction, 0%). It
was unknown whether the incomplete apposition was already
present at baseline, because no IVUS assessment was per-
formed after procedure. Between 6 and 12 months, no
additional MACE was reported.
Angiographic and IVUS Outcome
Of 28 patients, 25 (89%) underwent 6-month follow-up
angiography. Binary angiographic restenosis was docu-
mented in 4 patients (16%). One of these patients had target
vessel total occlusion. Two paclitaxel-eluting stents had been
implanted to treat ISR of a covered stent, which had been
used to treat ISR of a gold-coated stent. Additional interven-
tion was not undertaken, because the patient had no anginal
symptoms.
Of the remaining 3 patients, 1 had restenosis in a bare
metal stent implanted because of a dissection at the distal
edge of the paclitaxel-eluting stent. Two patients had reste-
nosis in a gap between 2 paclitaxel-eluting stents, as evident
on IVUS (Figure 1). Minimal neointimal hyperplasia is seen
in the segments with double contours of stent struts; however,
where there is a single layer of stent struts, ie, a gap between
the paclitaxel-eluting stents, occlusive neointimal tissue is
evident. Hence, of the 4 with binary restenosis, 3 occurred
within a region with no local delivery of paclitaxel.
The quantitative coronary angiographic data are summa-
rized in Table 4. The mean reference vessel diameter was
2.75 mm. Figure 2 shows the cumulative distribution curve of
MLD in the in-stent segment. The MLD at follow-up
(1.84 mm) was significantly lower than that after procedure
(2.40 mm). Diameter stenosis at follow-up was 30.8%, with
an average in-stent late loss of 0.54 mm. Late loss of the
proximal and distal edges were 0.20 and 0.11 mm, respec-
tively, without angiographic restenosis.
Seventeen patients underwent IVUS examination at
follow-up. The neointimal hyperplasia volume amounted to
20.323.1 mm3 with the stent volume of 172.185.4 mm3.
In addition, serial analysis (n14 pairs) of the total vessel
volume after procedure (411.2332.9 mm3) versus follow-up
(435.8217.5 mm3) showed no statistically significant
change, suggesting that paclitaxel-eluting stent does not cause
positive or negative vessel remodeling. No late acquired
incomplete stent apposition was detected by serial IVUS
investigation.
Subgroup Analysis
We performed subgroup analysis to estimate the treatment
effect within stented segments directly exposed to local
paclitaxel delivery by excluding the 3 patients who showed
restenosis in a bare stent or a gap between 2 paclitaxel-eluting
stents, as tabulated in Table 4. In this subgroup, the late loss
and restenosis rate was 0.47 mm and 4.5%, respectively.
Figure 1. The IVUS images at follow-up of a patient who
showed restenosis in a gap between the 2 paclitaxel-eluting
stents (PES). Minimal neointimal hyperplasia was observed
within the PES (A and C), whereas neointimal hyperplasia was
noted in a gap (B). The cross-sectional views (A, B, and C) cor-
respond to the a, b, and c sections of the longitudinal views.
Figure 2. The cumulative distribution curve of the MLD.
TABLE 3. Cumulative Clinical Outcome
30 Days 6 Months 12 Months
Death 0 0 0
Q-wave MI 0 0 0
Non–Q-wave MI 1 (3.6) 1 (3.6) 1 (3.6)
CABG 0 1 (3.6) 1 (3.6)
Target vessel revascularization 0 6 (21.4) 6 (21.4)
Values are presented as numbers (relative percentages).
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Figure 3 shows the results of subgroup analysis between
patients with single stent (n13) and those with 2 stents
(n12). Post-hoc statistical analysis showed a significantly
smaller MLD and larger diameter stenosis at follow-up for
the 2-stent group (P0.01). Post-hoc statistical analysis of
IVUS data at follow-up reveal that percent volume obstruc-
tion in the single-stent group (n10; length, 15.42.8 mm)
was 12.415.7% for a stent volume of 111.927.9 mm3,
whereas percent volume obstruction in the 2-stent group
(n7, length 29.43.0 mm) was 10.18.2% for a stent
volume of 258.160.3 mm3. In this latter group, the analysis
included only 1 of the 4 patients who had angiographic
restenosis.
Discussion
In the present study, we report the first clinical experience
with the TAXUS NIRx paclitaxel-eluting stent for the treat-
ment of ISR. The major findings of the TAXUS III trial are
as follows. First, this polymer-based paclitaxel-eluting stent
is feasible and safe for the treatment of ISR with no subacute
stent thrombosis. Second, late loss (0.54 mm) is seemingly
diminished compared with historical controls. Third, angio-
graphic restenosis rate is 16%; however, when present, it
tends to occur in a gap between 2 paclitaxel-eluting stents.
Fourth, the TLR rate of 21.4% (6 of 28 patients) is promising
given that 3 were not performed according to predefined
angiographic criteria.
Safety Consideration
At up to 12 months of clinical follow-up, there has been no
late subacute stent thrombosis in our patient population,
although clopidogrel was discontinued at 6 months. There
was 1 patient with silent total occlusion who had preexisting
in-stent restenosis in gold-coated and covered stent sandwich
subsequently treated with the study stents. However, the
mechanism of this occlusion is difficult to decipher, because
the effect of paclitaxel on the adjacent covered stent sandwich
is unknown and the covered stent precluded the IVUS
assessment with respect to the detection of either a gap or an
overlap. The promising safety data in our study contrasts with
Figure 3. Post-hoc analysis between sin-
gle stent and 2 stents of angiographic
parameters (MLD at follow-up, percent
diameter stenosis (DS) at follow-up, and
late loss). It has to be emphasized that
the 2 stent group include 1 total occlu-
sion, 2 gaps between the stents, and 1
bare-stent restenosis. *P0.01 vs 2
stents by unpaired t test; †P0.054 ver-
sus 2 stents.











Before procedure, mm 28 NA 2.751.20 NA 25 2.841.25
After procedure, mm 28 3.080.40 2.910.43 2.810.43 25 2.910.45
6-Month follow-up, mm 25 2.860.43† 2.670.42† 2.540.43† 22 2.640.45†
Minimal lumen diameter
Before procedure, mm 28 NA 0.870.38 NA 25 0.900.39
After procedure, mm 28 2.670.54 2.400.44 2.270.47 25 2.410.46
6-Month follow-up, mm 25 2.450.54† 1.840.63† 2.170.49 22 1.930.61†
Percent diameter stenosis
Before procedure, mm 28 NA 67.311.3 NA 25 67.111.8
After procedure, mm 28 13.99.4 17.47.6 19.311.0 25 16.97.6
6-Month follow-up, mm 25 14.310.5 30.820.5† 14.89.5 22 26.918.6†
Late loss, mm 25 0.200.40 0.540.51 0.110.33 22 0.470.48
*The subgroup is the group that excludes the patients who showed angiographic restenosis in a bare metal stent or a gap between
the paclitaxel-eluting stents.
†P0.05 vs after procedure.
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the high incidence of late subacute stent thrombosis in the
randomized Score trial, evaluating de novo lesions with the
QuaDS stent that used 4 or 5 polymer sleeves to deliver high
concentrations (800 g/sleeve) of paclitaxel derivative.28 The
enrollment of the Score trial was prematurely stopped be-
cause of a major imbalance in MACE between the study and
control groups associated with stent thrombosis. Previous
animal studies showed that paclitaxel may delay the healing
process in a dose-dependent manner,29 and stent thrombosis is
likely the result of incomplete healing and reendotheli-
alization. Additional preclinical and clinical data will give
insight as to whether the dose of paclitaxel (1.0 g/mm2
[loaded drug/stent surface area]) used in this trial will
maintain the promising safety margin.
Efficacy of the TAXUS NIRx Paclitaxel-Eluting
Stent for Treatment of In-Stent Restenosis
Previous reports using bare metal stent for treatment of ISR
showed a late loss of 0.9 to 1.4 mm.30–32 The overall late loss
(0.54 mm) in our study was more favorable, even though it
underestimates the treatment effect. If the 2 patients with
restenosis attributable to a gap between 2 paclitaxel-eluting
stents and the patient with restenosis in a bare stent are
excluded, the adjusted late loss is 0.47 mm. In addition, the
late loss in the single-stent group was 0.36 mm (Figure 3).
These values are close to the loss of 0.35 mm (placebo group,
0.70 mm) observed in the TAXUS I trial on de novo coronary
lesions treated with the same slow-release formulation. Fur-
thermore, the neointimal volume from the TAXUS III pa-
tients with 1 NIRx stent was 15.6 mm3, comparable to
14.8 mm3 in the TAXUS I patients treated with one NIRx
stent. These two values are both lower than the value of
21.6 mm3 seen in the TAXUS I uncoated bare stent group.
Taken together, these data suggest that paclitaxel on the NIRx
seems to attenuate neointimal formation for ISR as well as de
novo lesions.
Restenosis at the Gap
In 2 patients, IVUS identified a gap between 2 eluting stents
that led to restenosis. Our hypothesis is that barotrauma from
balloon inflation in an area of preexisting in-stent neointima
may have triggered the local exuberant hyperplasia in the gap
where the concentration of paclitaxel is insufficient to prevent
neointimal hyperplasia. Accordingly, we speculate that pac-
litaxel does not diffuse substantially from the edge of the
stent to have biological effect in the gap. Therefore, when
treating ISR with the paclitaxel-eluting stents, covering the
entire length of the previously implanted stents and providing
a margin at either side may reduce TLR associated with
restenosis near the drug-treated segments. With this in mind,
IVUS guidance may be useful, and the advent of longer-
eluting stents will be advantageous.
TLR Without Angiographic Restenosis
The TLR rate of this trial has been artificially inflated by
reinterventions because of ultrasound or angiographic find-
ings not always clinically driven or justified by predefined
angiographic criteria. In this trial, 3 of 6 TLRs had diameter
stenosis 50%. Two of these patients underwent TLR as a
result of IVUS findings at follow-up. In one, there was an
incomplete apposition at follow-up without postprocedural
assessment. In the other patient, the stent was considered at
follow-up to be insufficiently expanded, although the mean
lumen area of the stent was 4.41 mm2 without neointimal
hyperplasia. The third patient had anginal symptoms despite
a diameter stenosis of 32.5% and underwent TLR in an
attempt to increase the MLD (1.33 mm) and reference
diameter (1.96 mm). In this trial, the incidence of TLR may
underestimate the clinical benefit related to the inhibition of
neointimal hyperplasia resulting from the drug elution.
Study Limitations
The limitations of this study are its small sample size and
single-arm open-label design without randomization. The
angiographic follow-up rate was acceptable, although a
higher IVUS follow-up rate may have provided more infor-
mation on neointimal hyperplasia. Ongoing clinical follow-up
will provide insight on long-term outcomes in this challeng-
ing population.
Conclusion
Paclitaxel-eluting stent implantation is considered safe and
potentially efficacious in the treatment of ISR. The IVUS
guidance to ensure good stent deployment with complete
coverage of target lesion may reduce reintervention.
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